RxDoctor Payments Data

Cassandra Heuer

Psychiatric/Mental Health · Pierre, SDNPI 1669936829

Payments from drug & device makers

What this record shows

Neuronetics, Inc. accounts for 82.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,159, more than ten times the $111 reported in 2021.

$2,458in general payments, 2019–2025

Across 22 payments — averaging $111.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$2K
  • Alkermes, Inc.$151
  • Otsuka America Pharmaceutical, Inc.$123
  • Johnson & Johnson$71
  • AbbVie$61
  • Sunovion Pharmaceuticals Inc.$12
  • plus $24 from 2 others

What the payments were for

  • Travel & lodging$1,42358%
  • Food & beverage$1,03542%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,458 in reported general payments places this provider in the 85th percentile of 77 psychiatric/mental health providers in South Dakota.

See all psychiatric/mental health providers in South Dakota

Medicare billing

Part B allowed, 2024
$24,659
Medicare patients
58
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate59$151,853
Austedo XrDeutetrabenazine25$123,881
AristadaAripiprazole Lauroxil24$56,650
RexultiBrexpiprazole27$39,591
TrintellixVortioxetine Hydrobromide45$21,300
BelsomraSuvorexant34$13,230
Aripiprazole57$3,296
Lisdexamfetamine Dimesylate17$3,232
Clozapine50$2,528
Divalproex Sodium ErDivalproex Sodium45$1,756
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,114
Atomoxetine Hcl13$937
Bupropion XlBupropion Hcl55$803
Ziprasidone Hcl31$725
Olanzapine48$686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$71$151,85359 claims
Alkermes, Inc.Aristada$151$56,65024 claims
Otsuka America Pharmaceutical, Inc.Rexulti$123$39,59127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 psychiatric/mental health providers in South Dakota.

Other psychiatric/mental health in Pierre

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →